Michael Keller, M.D., is a pediatric immunologist at Children's National Health System. He is a specialist in the diagnosis and treatment of primary and secondary disorders of immunity. He is board-certified in allergy and immunology, as well as pediatrics, and is a member of the American Academy of Allergy, Asthma, and Immunology; the Clinical Immunology Society; and the European Society of Immunodeficiency. He is also an active member of the Primary Immunodeficiency Treatment Consortium (PIDTC).
Dr. Keller has authored many peer-reviewed articles and abstracts and is a member of the AAAAI/ACAAI practice parameter committee for Treatment and Diagnosis of Primary Immunodeficiency Disorders. His specialties include disorders of immunity and care of immunologically vulnerable patients.
Dr. Keller's research interests focus on the use of antiviral T-cell therapies in bone marrow transplantation, including expanding the use of this therapy to benefit children with primary immunodeficiency disorders. He is associated with the Center for Emerging Technologies in Immune cell therapies, under Dr. Catherine Bollard.